Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

医学 帕博西利布 耐受性 内科学 来曲唑 富维斯特朗 肿瘤科 不利影响 转移性乳腺癌 乳腺癌 癌症 三苯氧胺
作者
Komal Jhaveri,Melissa Accordino,Philippe L. Bédard,Andrés Cervantes,Valentina Gambardella,Erika Hamilton,Antoîne Italiano,Kevin Kalinsky,Ian E. Krop,Mafalda Oliveira,Peter Schmid,Cristina Saura,Nicholas C. Turner,Andréa Varga,Sravanthi Cheeti,Stephanie Hilz,Katherine E. Hutchinson,Yanling Jin,Stephanie Royer‐Joo,Ubong Peters
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (33): 3947-3956 被引量:14
标识
DOI:10.1200/jco.24.00110
摘要

PURPOSE To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in combination with palbociclib and endocrine therapy (ET), in a phase I/Ib study in patients with PIK3CA -mutated, hormone receptor–positive/human epidermal growth factor receptor 2–negative locally advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT03006172 ). METHODS Women ≥18 years of age received inavolisib, palbociclib, and letrozole (Inavo + Palbo + Letro arm) or fulvestrant (Inavo + Palbo + Fulv arm) until unacceptable toxicity or disease progression. The primary objective was to evaluate safety or tolerability. RESULTS Fifty-three patients were included, 33 in the Inavo + Palbo + Letro arm and 20 in the Inavo + Palbo + Fulv arm. Median duration of inavolisib treatment was 15.7 and 20.8 months (cutoff: March 27, 2023), respectively. Treatment-related adverse events (TRAEs) occurred in all patients; the most frequent were stomatitis, hyperglycemia, and diarrhea; grade ≥3 any TRAE rates were 87.9% and 85.0%; 6.1% and 10.0% discontinued any treatment due to TRAEs in the Inavo + Palbo + Letro and Inavo + Palbo + Fulv arms, respectively. No PK drug–drug interactions (DDIs) were observed among the study treatments when administered. Confirmed objective response rates were 52.0% and 40.0% in patients with measurable disease, and median progression-free survival was 23.3 and 35.0 months in the Inavo + Palbo + Letro and Inavo + Palbo + Fulv arms, respectively. Available paired pre- and on-treatment tumor tissue and circulating tumor DNA analyses confirmed the effects of study treatment on pharmacodynamic and pathophysiologic biomarkers of response. CONCLUSION Inavolisib plus palbociclib and ET demonstrated a manageable safety profile, lack of DDIs, and promising preliminary antitumor activity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xqwwqx发布了新的文献求助10
1秒前
不明完成签到 ,获得积分10
1秒前
田様的应助被马梦乐采纳,获得10
2秒前
想毕业完成签到,获得积分10
2秒前
yan完成签到 ,获得积分10
2秒前
2秒前
1234完成签到 ,获得积分10
2秒前
2秒前
zzhbby完成签到,获得积分10
2秒前
2秒前
syalonyui完成签到,获得积分10
4秒前
DongNingGao发布了新的文献求助10
5秒前
6秒前
SciGPT的应助被zzhbby采纳,获得10
7秒前
马梦乐完成签到,获得积分10
8秒前
Aru发布了新的文献求助10
8秒前
8秒前
十二完成签到,获得积分10
9秒前
10秒前
11秒前
11秒前
12秒前
稀松完成签到,获得积分10
12秒前
科研通AI2S的应助被WYL采纳,获得10
13秒前
14秒前
UNIQUE完成签到,获得积分10
14秒前
高梓轩完成签到,获得积分10
15秒前
15秒前
xx发布了新的文献求助10
16秒前
16秒前
16秒前
17秒前
17秒前
王乐乐发布了新的文献求助10
17秒前
草莓熊完成签到 ,获得积分10
17秒前
sweet雪儿妞妞完成签到 ,获得积分10
18秒前
ding的应助被moon采纳,获得10
18秒前
时尚青雪发布了新的文献求助10
18秒前
欢喜代桃发布了新的文献求助10
19秒前
御景风完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190724
求助须知:如何正确求助?哪些是违规求助? 9577784
关于积分的说明 21855018
捐赠科研通 7789883
什么是DOI,文献DOI怎么找? 3436455
关于科研通互助平台的介绍 2560308
邀请新用户注册赠送积分活动 2483172